Correction for “Macrophage‐derived extracellular vesicles mediate smooth muscle hyperplasia: role of altered miRNA cargo in response to HIV infection and substance abuse,” by Himanshu Sharma, Mahendran Chinnappan, Stuti Agarwal, Pranjali Dalvi, Sumedha Gunewardena, Amy O’Brien‐Ladner, and Navneet K. Dhillon, which was first published April 19, 2018; 10.1096/fj.201701558R (FASEB J. 32, 5174–5185).
The authors report that images of human pulmonary arterial smooth muscle cells (HPASMCs) showing hyperproliferation on treatment with HIV‐infected and/or cocaine‐treated monocyte macrophage‐derived EVs in Figure 2F are actually images of human pulmonary microvascular endothelial cells (HPMECs). While working on this manuscript, the authors were also, in parallel, investigating the effect of EVs on endothelial cell proliferation; hence, at some point, HPMEC images were unintentionally misplaced as HPASMCs. Since both the cell types showed similar response under the same experimental conditions, this correction will not change any result interpretation or conclusion of the article. The authors regret any inconvenience caused by this error.
FIGURE 2.
Increased SMC proliferation on uptake of H+C‐ or cocaine‐treated MDM–derived EVs. (A,B) Monomac‐1–derived macrophages were treated with H+C in the presence or absence of GW4869 (1 or 10 μM). Supernatants collected were added on HPASMCs in 1:1 ratio with SMC medium followed by a cell proliferation assay after 2 and 4 d. (C) Uptake of EVs by SMCs. EVs were labeled with fluorescent PKH67 dye (green) and added on HPASMCs (10 μg/24 well) for 2 h. Cells were later washed and fixed, followed by staining with phalloidin (red). (D–F) Exosomes (2 μg) resuspended in PBS, isolated from untreated, cocaine (Coc) treated, HIV‐1 infected and from both HIV‐1‐infected and cocaine‐treated monomac‐1 (D) or primary human monocyte (E) derived macrophages were added to 0.1% serum‐starved HPASMCs overnight followed by replenishing the medium the next day. MTS cell proliferation assay was performed at 48 h after exosome treatment. (F) Representative images of HPASMCs treated with EVs. (G) Western blot analysis of HPASMC total cell extract after 48 h of EV treatment for proliferation marker, PCNA. Data are means ± SD from ≥3 independent experiments. *p < .05, **p < .01, ***p < .001 versus control; # p < .05, ## p < .01, ### p < .001 versus cocaine; $ p < .05, $$$ p < .001 versus HIV